Analysis of antihypertensive treatment using real-world Japanese data—the retrospective study of antihypertensives for lowering blood pressure (REAL) study
Hypertension requires strict treatment because it causes diseases that can lead to death. Although various classes of antihypertensive drugs are available, the actual status of antihypertensive drug selection and the transition in prescription patterns over time have not been fully examined. Therefo...
Gespeichert in:
| Veröffentlicht in: | Hypertension research Jg. 42; H. 7; S. 1057 - 1067 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Nature Publishing Group
01.07.2019
Springer Singapore |
| Schlagworte: | |
| ISSN: | 0916-9636, 1348-4214, 1348-4214 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Hypertension requires strict treatment because it causes diseases that can lead to death. Although various classes of antihypertensive drugs are available, the actual status of antihypertensive drug selection and the transition in prescription patterns over time have not been fully examined. Therefore, we conducted a claims-based study using two claims databases (2008–16) to determine this status in Japan. We examined the prescription rate for each class of antihypertensive drugs in hypertensive patients and compared the patients’ ages and the sizes of the medical institutions treating these patients. Among the 1 560 865 and 302 433 hypertensive patients in each database, calcium channel blockers (CCBs) (>60%) and angiotensin II receptor blockers (ARBs) (>55%) were the most frequently prescribed classes. The prescription rate of CCBs increased and ARBs decreased with the patients’ ages. Although the Japanese guidelines for management of hypertension in 2014 changed the recommendation and indicated that β-blockers should not be used as first-line drugs, their prescription status did not change during this study period up to 2016. Use of CCBs and ARBs as first-line drugs differed by the types of patient comorbidities. Although ARBs or angiotensin-converting enzyme inhibitors were recommended for patients with some comorbidities, CCBs were used relatively frequently. In conclusion, the patients’ ages and comorbidities and the sizes of the medical institutions affect the selection of antihypertensive drugs. Selection and use of drugs may not always follow the guidelines. |
|---|---|
| AbstractList | Hypertension requires strict treatment because it causes diseases that can lead to death. Although various classes of antihypertensive drugs are available, the actual status of antihypertensive drug selection and the transition in prescription patterns over time have not been fully examined. Therefore, we conducted a claims-based study using two claims databases (2008-16) to determine this status in Japan. We examined the prescription rate for each class of antihypertensive drugs in hypertensive patients and compared the patients' ages and the sizes of the medical institutions treating these patients. Among the 1 560 865 and 302 433 hypertensive patients in each database, calcium channel blockers (CCBs) (>60%) and angiotensin II receptor blockers (ARBs) (>55%) were the most frequently prescribed classes. The prescription rate of CCBs increased and ARBs decreased with the patients' ages. Although the Japanese guidelines for management of hypertension in 2014 changed the recommendation and indicated that β-blockers should not be used as first-line drugs, their prescription status did not change during this study period up to 2016. Use of CCBs and ARBs as first-line drugs differed by the types of patient comorbidities. Although ARBs or angiotensin-converting enzyme inhibitors were recommended for patients with some comorbidities, CCBs were used relatively frequently. In conclusion, the patients' ages and comorbidities and the sizes of the medical institutions affect the selection of antihypertensive drugs. Selection and use of drugs may not always follow the guidelines. Hypertension requires strict treatment because it causes diseases that can lead to death. Although various classes of antihypertensive drugs are available, the actual status of antihypertensive drug selection and the transition in prescription patterns over time have not been fully examined. Therefore, we conducted a claims-based study using two claims databases (2008-16) to determine this status in Japan. We examined the prescription rate for each class of antihypertensive drugs in hypertensive patients and compared the patients' ages and the sizes of the medical institutions treating these patients. Among the 1 560 865 and 302 433 hypertensive patients in each database, calcium channel blockers (CCBs) (>60%) and angiotensin II receptor blockers (ARBs) (>55%) were the most frequently prescribed classes. The prescription rate of CCBs increased and ARBs decreased with the patients' ages. Although the Japanese guidelines for management of hypertension in 2014 changed the recommendation and indicated that β-blockers should not be used as first-line drugs, their prescription status did not change during this study period up to 2016. Use of CCBs and ARBs as first-line drugs differed by the types of patient comorbidities. Although ARBs or angiotensin-converting enzyme inhibitors were recommended for patients with some comorbidities, CCBs were used relatively frequently. In conclusion, the patients' ages and comorbidities and the sizes of the medical institutions affect the selection of antihypertensive drugs. Selection and use of drugs may not always follow the guidelines.Hypertension requires strict treatment because it causes diseases that can lead to death. Although various classes of antihypertensive drugs are available, the actual status of antihypertensive drug selection and the transition in prescription patterns over time have not been fully examined. Therefore, we conducted a claims-based study using two claims databases (2008-16) to determine this status in Japan. We examined the prescription rate for each class of antihypertensive drugs in hypertensive patients and compared the patients' ages and the sizes of the medical institutions treating these patients. Among the 1 560 865 and 302 433 hypertensive patients in each database, calcium channel blockers (CCBs) (>60%) and angiotensin II receptor blockers (ARBs) (>55%) were the most frequently prescribed classes. The prescription rate of CCBs increased and ARBs decreased with the patients' ages. Although the Japanese guidelines for management of hypertension in 2014 changed the recommendation and indicated that β-blockers should not be used as first-line drugs, their prescription status did not change during this study period up to 2016. Use of CCBs and ARBs as first-line drugs differed by the types of patient comorbidities. Although ARBs or angiotensin-converting enzyme inhibitors were recommended for patients with some comorbidities, CCBs were used relatively frequently. In conclusion, the patients' ages and comorbidities and the sizes of the medical institutions affect the selection of antihypertensive drugs. Selection and use of drugs may not always follow the guidelines. |
| Author | Yoshida, Takuo Oh, Akinori Iwasaki, Kosuke Shimasaki, Yukio Ohishi, Mitsuru Otsuka, Yujiro Hiroi, Shinzo Takeshima, Tomomi |
| Author_xml | – sequence: 1 givenname: Mitsuru surname: Ohishi fullname: Ohishi, Mitsuru – sequence: 2 givenname: Takuo surname: Yoshida fullname: Yoshida, Takuo – sequence: 3 givenname: Akinori surname: Oh fullname: Oh, Akinori – sequence: 4 givenname: Shinzo surname: Hiroi fullname: Hiroi, Shinzo – sequence: 5 givenname: Tomomi surname: Takeshima fullname: Takeshima, Tomomi – sequence: 6 givenname: Yujiro surname: Otsuka fullname: Otsuka, Yujiro – sequence: 7 givenname: Kosuke surname: Iwasaki fullname: Iwasaki, Kosuke – sequence: 8 givenname: Yukio surname: Shimasaki fullname: Shimasaki, Yukio |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30842611$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks9qFTEYxYNU7G31AdxIwE1djObLZDLJRriU-o8Lgug6ZDKZ3pTcyZhkWu7Oh3Dry_kkZritaNFVCDnnx8n3nRN0NIbRIvQUyEsgtXiVGDBGKgKyIrQWFX2AVlAzUTEK7AitiAReSV7zY3SS0hUhVDQSHqHjmghGOcAK_ViP2u-TSzgMWI_ZbfeTjdmOyV1bnKPVeWfHjOfkxktcrr66CdH3-IOe9GiTxb3O-ue373lry3OOIU3W5MWc8tzv_4VNeAgR-3Bj4wLtfAg9nqJNaY4Wn326WG9eHNyP0cNB-2Sf3J6n6Mubi8_n76rNx7fvz9ebyjTQ5qql1EhpaAfQ6XaooeOMN7ofGKec9W1L7ECB6MFIYKaTAEa2negJ9JY3vK1P0esDd5q7ne1N-XHUXk3R7XTcq6Cd-vtldFt1Ga6VIG0jBCmAs1tADF9nm7LauWSs92VGYU6KghBS1FLSIn1-T3oV5li2UFSUEagLUxbVsz8T_Y5yt7kiaA8CU0aeoh2UcVlnF5aAzisgaumIOnRElY6opSNqCQD3nHfw_3t-AW53w4o |
| CitedBy_id | crossref_primary_10_1097_HJH_0000000000003186 crossref_primary_10_1111_jch_14938 crossref_primary_10_1080_07853890_2022_2162113 crossref_primary_10_1093_jphsr_rmaa017 crossref_primary_10_1007_s40256_023_00625_1 crossref_primary_10_1038_s41440_024_01875_5 crossref_primary_10_1080_14656566_2020_1724958 crossref_primary_10_1093_ehjcvp_pvaf001 crossref_primary_10_2147_DDDT_S518377 crossref_primary_10_1038_s41598_025_91187_6 crossref_primary_10_2147_CLEP_S265966 crossref_primary_10_1038_s41440_020_0398_0 crossref_primary_10_1080_10641963_2021_2022688 crossref_primary_10_1002_jcph_1685 crossref_primary_10_1038_s41440_024_01954_7 crossref_primary_10_1111_jch_14705 crossref_primary_10_1111_jch_14947 crossref_primary_10_1038_s41440_024_01896_0 crossref_primary_10_1016_j_jacl_2024_12_006 crossref_primary_10_1038_s41440_023_01452_2 crossref_primary_10_1016_j_amjmed_2024_10_016 crossref_primary_10_1007_s00228_022_03369_0 crossref_primary_10_1016_j_clinthera_2025_07_024 crossref_primary_10_1038_s41440_022_00872_w crossref_primary_10_1038_s41440_019_0365_9 crossref_primary_10_1038_s41440_023_01373_0 |
| Cites_doi | 10.1291/hypres.29.S1 10.1038/hr.2016.96 10.1038/hr.2016.158 10.1038/hr.2012.216 10.1016/S0140-6736(00)03307-9 10.1038/hr.2017.56 10.1097/HJH.0b013e328340d76f 10.1161/01.HYP.27.4.914 10.1038/hr.2016.120 10.1253/circj.CJ-13-0847 10.1038/hr.2013.80 10.1097/HJH.0b013e328359a9f7 10.1155/2014/621437 10.3143/geriatrics.54.G2 10.1038/hr.2013.128 10.1056/NEJMoa0801369 10.1038/ajh.2008.356 10.1136/bmj.b1665 10.1056/NEJMoa1511939 10.1161/01.HYP.18.1.67 |
| ContentType | Journal Article |
| Copyright | This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2019 |
| Copyright_xml | – notice: This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
| DOI | 10.1038/s41440-019-0238-2 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Medical Library (Alumni) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Academic Middle East (New) CrossRef MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1348-4214 |
| EndPage | 1067 |
| ExternalDocumentID | PMC8075880 30842611 10_1038_s41440_019_0238_2 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GroupedDBID | --- -Q- 0R~ 29I 39C 4.4 406 5GY 70F 7X7 88E 8FI 8FJ AACDK AANZL AASML AATNV AAYXX ABAKF ABBRH ABDBE ABFSG ABJNI ABLJU ABRTQ ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMJI ACRQY ACSTC ACZOJ ADBBV AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AEZWR AFBBN AFDZB AFFHD AFHIU AFKRA AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AHWEU AIGIU AILAN AIXLP AJRNO ALFFA ALMA_UNASSIGNED_HOLDINGS AMYLF ATHPR AXYYD AYFIA BENPR BKKNO BPHCQ BVXVI CCPQU CITATION CS3 DNIVK DPUIP DU5 E3Z EBLON EBS EE. EIOEI EJD F5P FDQFY FERAY FIGPU FIZPM FSGXE FYUFA GX1 HMCUK HZ~ IWAJR JSH JSO JZLTJ LGEZI LOTEE M1P NADUK NQJWS NXXTH O9- OK1 P2P PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO RNT RNTTT ROL SNX SNYQT SOHCF SOJ SRMVM SWTZT TAOOD TBHMF TDRGL TSG UKHRP XSB .55 2WC 53G ABAWZ AESKC ALIPV BAWUL CGR CUY CVF DIK ECM EIF EMB EMOBN JSF KQ8 NPM RJT RZJ SV3 TKC TR2 W2D X7M 3V. 7XB 8FK K9. PKEHL PQEST PQUKI 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c517t-722c99c2b11ba7f31b6465adf46264d770ef210afc914cb911c97b8d01de65673 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 28 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000474350700015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0916-9636 1348-4214 |
| IngestDate | Tue Nov 04 01:52:12 EST 2025 Fri Sep 05 08:27:26 EDT 2025 Tue Oct 07 06:39:04 EDT 2025 Mon Jul 21 05:13:59 EDT 2025 Tue Nov 18 22:34:21 EST 2025 Sat Nov 29 06:23:31 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Diuretics Calcium channel blockers Antihypertensive agents Real-world data Angiotensin II receptor antagonists |
| Language | English |
| License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c517t-722c99c2b11ba7f31b6465adf46264d770ef210afc914cb911c97b8d01de65673 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8075880 |
| PMID | 30842611 |
| PQID | 2240138079 |
| PQPubID | 2043497 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8075880 proquest_miscellaneous_2188983992 proquest_journals_2240138079 pubmed_primary_30842611 crossref_citationtrail_10_1038_s41440_019_0238_2 crossref_primary_10_1038_s41440_019_0238_2 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-07-01 |
| PublicationDateYYYYMMDD | 2019-07-01 |
| PublicationDate_xml | – month: 07 year: 2019 text: 2019-07-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Tokyo – name: Singapore |
| PublicationTitle | Hypertension research |
| PublicationTitleAlternate | Hypertens Res |
| PublicationYear | 2019 |
| Publisher | Nature Publishing Group Springer Singapore |
| Publisher_xml | – name: Nature Publishing Group – name: Springer Singapore |
| References | A Ikeda (238_CR2) 2009; 22 Japan Society of Hypertension. (238_CR14) 2013; 36 MH Weinberger (238_CR22) 1991; 18 F Saito (238_CR23) 1996; 27 S Hiroi (238_CR10) 2016; 39 NS Beckett (238_CR5) 2008; 358 MR Law (238_CR6) 2009; 338 K Miura (238_CR15) 2013; 77 B Neal (238_CR4) 2000; 356 M Janic (238_CR19) 2014; 2014 Japanese Society of Hypertension. (238_CR7) 2006; 29 S Tani (238_CR17) 2017; 40 238_CR20 N Takashima (238_CR3) 2012; 30 K Shimamoto (238_CR9) 2014; 37 T Kohro (238_CR11) 2013; 36 S Umemoto (238_CR18) 2017; 40 The Japan Geriatrics Society. (238_CR21) 2017; 54 T Ogihara (238_CR8) 2009; 32 238_CR13 A Ibaraki (238_CR12) 2017; 40 238_CR16 DJ Trevisol (238_CR1) 2011; 29 |
| References_xml | – volume: 29 start-page: S1 year: 2006 ident: 238_CR7 publication-title: Hypertens Res doi: 10.1291/hypres.29.S1 – volume: 39 start-page: 907 year: 2016 ident: 238_CR10 publication-title: Hypertens Res doi: 10.1038/hr.2016.96 – volume: 40 start-page: 376 year: 2017 ident: 238_CR18 publication-title: Hypertens Res doi: 10.1038/hr.2016.158 – volume: 36 start-page: 559 year: 2013 ident: 238_CR11 publication-title: Hypertens Res doi: 10.1038/hr.2012.216 – ident: 238_CR13 – volume: 356 start-page: 1955 year: 2000 ident: 238_CR4 publication-title: Lancet doi: 10.1016/S0140-6736(00)03307-9 – volume: 40 start-page: 892 year: 2017 ident: 238_CR17 publication-title: Hypertens Res doi: 10.1038/hr.2017.56 – volume: 29 start-page: 179 year: 2011 ident: 238_CR1 publication-title: J Hypertens doi: 10.1097/HJH.0b013e328340d76f – volume: 27 start-page: 914 year: 1996 ident: 238_CR23 publication-title: Hypertension doi: 10.1161/01.HYP.27.4.914 – volume: 40 start-page: 203206 year: 2017 ident: 238_CR12 publication-title: Hypertens Res doi: 10.1038/hr.2016.120 – volume: 77 start-page: 2226 year: 2013 ident: 238_CR15 publication-title: Circ J doi: 10.1253/circj.CJ-13-0847 – volume: 37 start-page: 253 year: 2014 ident: 238_CR9 publication-title: Hypertens Res doi: 10.1038/hr.2013.80 – volume: 30 start-page: 2299 year: 2012 ident: 238_CR3 publication-title: J Hypertens doi: 10.1097/HJH.0b013e328359a9f7 – volume: 2014 start-page: 621437 year: 2014 ident: 238_CR19 publication-title: Biomed Res Int doi: 10.1155/2014/621437 – volume: 54 start-page: 236 year: 2017 ident: 238_CR21 publication-title: Nihon Ronen Igakkai Zasshi doi: 10.3143/geriatrics.54.G2 – volume: 36 start-page: 923 year: 2013 ident: 238_CR14 publication-title: Hypertens Res doi: 10.1038/hr.2013.128 – volume: 358 start-page: 1887 year: 2008 ident: 238_CR5 publication-title: N Engl J Med doi: 10.1056/NEJMoa0801369 – ident: 238_CR20 – volume: 22 start-page: 273 year: 2009 ident: 238_CR2 publication-title: Am J Hypertens doi: 10.1038/ajh.2008.356 – volume: 338 start-page: b1665 year: 2009 ident: 238_CR6 publication-title: Brit Med J doi: 10.1136/bmj.b1665 – volume: 32 start-page: 3 year: 2009 ident: 238_CR8 publication-title: Hypertens Res – ident: 238_CR16 doi: 10.1056/NEJMoa1511939 – volume: 18 start-page: 67 year: 1991 ident: 238_CR22 publication-title: Hypertension doi: 10.1161/01.HYP.18.1.67 |
| SSID | ssj0028591 |
| Score | 2.388378 |
| Snippet | Hypertension requires strict treatment because it causes diseases that can lead to death. Although various classes of antihypertensive drugs are available, the... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1057 |
| SubjectTerms | Adrenergic beta-Antagonists - pharmacology Adrenergic beta-Antagonists - therapeutic use Adult Age Factors Aged Aged, 80 and over Angiotensin Receptor Antagonists - pharmacology Angiotensin Receptor Antagonists - therapeutic use Angiotensin-Converting Enzyme Inhibitors - pharmacology Angiotensin-Converting Enzyme Inhibitors - therapeutic use Antihypertensive Agents - pharmacology Antihypertensive Agents - therapeutic use Antihypertensives Blood Pressure - drug effects Calcium Channel Blockers - pharmacology Calcium Channel Blockers - therapeutic use Databases, Factual Diuretics Female Humans Hypertension Hypertension - drug therapy Japan Male Middle Aged Prescription drugs Retrospective Studies Treatment Outcome |
| Title | Analysis of antihypertensive treatment using real-world Japanese data—the retrospective study of antihypertensives for lowering blood pressure (REAL) study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30842611 https://www.proquest.com/docview/2240138079 https://www.proquest.com/docview/2188983992 https://pubmed.ncbi.nlm.nih.gov/PMC8075880 |
| Volume | 42 |
| WOSCitedRecordID | wos000474350700015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1348-4214 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0028591 issn: 0916-9636 databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1348-4214 dateEnd: 20191231 omitProxy: false ssIdentifier: ssj0028591 issn: 0916-9636 databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BixAX3o9AqYzEAZCsxk42tk-ooK0QKquqAmlvUew4dKXVpiS7nPkRXPlz_BJmnEdZQL1wiRTZeSgznofnyzcAz32iy0QWMRc-pt0qK7jxsuBSWlk4Y1xpA2X-sZrN9HxuTvoNt7aHVQ42MRjqsna0R35ArkcQO7p5ff6FU9coqq72LTSuwi61zSY9V_OLhIu42QLXnsg4Klo2VDUTfdCmoaoZ0y886LW43PZLfwWbf2Imf3NCR7f-9_Vvw80-_GSHnb7cgSt-dReuf-gL7Pfgx0BSwuqK4UdfnGGe2vQodzai0hnB5T8zPF3ywLnK3qPTpWaWjCCnP799x7gSh9dNPfzKyQKR7b9u2zIMnNmS2rXRTQOUngV87qbx7MXp9PD4ZXf1ffh0NP349h3vOzhwNxFqzZWUJG9phbCFqhJhszSbFGWVYh6VlkrFvsKcs6icEamzaHidUVaXsSg9BpoqeQA7q3rlHwFLjU8FGp_SZir12loMbVQxyTB_nCQ-TiKIB_nlrqc3py4byzyU2ROddyLPUeQ5iTyXEbwaLznvuD0um7w3CDbvl3mbX0g1gmfjMC5QqrrgV683OEdobTTx_0bwsNOh8WlJrCmFFRGoLe0aJxD59_bIanEWSMCJRBpt7-PLX-sJ3JBBxwlfvAc762bjn8I193W9aJv9sFrCUe_D7pvp7OT0F5r-IyE |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgoALb0qggJFAAiSrsZONnQNCFbRq6XaFUJH2FuLEaVdabUqyC-LGj-DKX-BH8UuYcR5lAfXWA8fIj0TO53nYM98APLaBzgOZ-lxYn06rjOCxlSmX0sg0i-MsN44yf6hGIz0ex29X4EeXC0NhlZ1MdII6LzM6I98g1SOIHT1-efyRU9Uoul3tSmg0sNizXz6jy1a_2H2N__eJlNtbB692eFtVgGcDoeZcSUnfII0QJlVFIEwURoM0L0K07cNcKd8W6AelRRaLMDMoDLJYGZ37Irdo_KgA5z0H51GOK3L21PjEwSMuOMftJyKOwI66W9RAb9Shu0X1KWUItSSXy3rwL-P2zxjN35Te9tX_bbmuwZXWvGabzX64Dit2dgMu7rcBBDfhe0fCwsqCIagmR-iHV20UP-uj7hmlAxwyfJxyxynL3qBRQcU6GYXU_vz6De1mbJ5XZZeqyhxR77-mrRk6BmxK5ehoUpcqwFz88aKy7Om7rc3hs2b0LXh_JotzG1Zn5czeARbGNhQoXHMTqdBqY9B0U-kgQv94EFg_8MDv8JJkLX07VRGZJi6MINBJA7EEIZYQxBLpwfN-yHHDXXJa5_UOSEkrxurkBEUePOqbUQDRrRKuernAPkLrWBO_sQdrDWb7twW-JhddeKCW0Nx3IHLz5ZbZ5MiRnBNJNuqWu6d_1kO4tHOwP0yGu6O9e3BZuv1FsdTrsDqvFvY-XMg-zSd19cDtVAYfzhrrvwAQQ3yl |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtQwEB6VLaq48P8TKGAkkKCStbGTjZMDQoXuitJltapA6i3EiUNXWm1KsgvixkNw5UV4HJ6EGecHFlBvPXCM7DiR83k8E3_zDcBD44WZJxOXC-PS3yoteGRkwqXUMkmjKM20lcwfq8kkPDqKphvwvc2FIVplaxOtoc6KlP6R92nrEaSOHvXzhhYx3Rs9O_nAqYIUnbS25TRqiByYz58wfKue7u_ht34k5Wj45sVL3lQY4OlAqCVXUtL7SC2ETlTuCR34wSDJch_9fD9TyjU5xkRJnkbCTzUahjRSOsxckRl0hJSH456DTYVOht-DzefDyfSwC_dIGc4q_YmAI8yD9kzVC_uVb89UXUogwj2Ty_Vd8S9X90_G5m9b4OjS_zx5l-Fi43iz3XqlXIENs7gKW68basE1-NbKs7AiZwi32TFG6GXD72cdH59RosB7hpdzbtVm2St0N6iMJyOy7Y8vX9GjxuZlWbRJrMxK-P5r2IphyMDmVKiOBrVJBMwyk1elYY8Ph7vjJ_Xd1-HtmUzODegtioW5BcyPjC_Q7GY6UL4JtUanTiWDADE38IzrOeC22InTRtid6ovMY0sw8MK4hluMcIsJbrF0YKe75aRWNTmt83YLqrgxcFX8C1EOPOia0TTReRPOerHCPiIMo5CUjx24WeO3e5rnhhS8CwfUGrK7DiR7vt6ymB1b-XOSz8Zd5_bpr3UfthDi8Xh_cnAHLki71IhkvQ29Zbkyd-F8-nE5q8p7zbJl8O6swf4TjvqGxQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Analysis+of+antihypertensive+treatment+using+real-world+Japanese+data%E2%80%94the+retrospective+study+of+antihypertensives+for+lowering+blood+pressure+%28REAL%29+study&rft.jtitle=Hypertension+research&rft.au=Ohishi+Mitsuru&rft.au=Yoshida+Takuo&rft.au=Oh+Akinori&rft.au=Hiroi+Shinzo&rft.date=2019-07-01&rft.pub=Nature+Publishing+Group&rft.issn=0916-9636&rft.eissn=1348-4214&rft.volume=42&rft.issue=7&rft.spage=1057&rft.epage=1067&rft_id=info:doi/10.1038%2Fs41440-019-0238-2&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0916-9636&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0916-9636&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0916-9636&client=summon |